Replimune Group Target Price

See Replimune Group's analyst price targets ($16) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.42

Average Target Price

$15.50

35.7% upside

6 analysts in the last 4 months

High: $20 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-07	BMO Capital	$20	75.1% upside
2026-08-07	WedbushRobert Driscoll	$19	66.4% upside
2026-08-04	Leerink PartnersDaina Graybosch	$17	48.9% upside
2026-07-31	WedbushRobert Driscoll	$12	5.1% upside
2026-06-30	Wedbush	$9	21.2% downside
2026-06-30	BMO CapitalEvan Seigerman	$16	40.1% upside
2026-02-05	Piper Sandler	$14	22.6% upside
2025-11-03	BMO CapitalEvan Seigerman	$11	3.7% downside
2025-10-27	H.C. Wainwright	$12	5.1% upside
2025-10-20	Wedbush	$18	57.6% upside
2025-01-22	BMO CapitalEvan Seigerman	$27	136.4% upside
2024-12-03	JefferiesRoger Song	$19	66.4% upside
2024-06-07	H.C. WainwrightRobert Burns	$17	48.9% upside
2024-06-04	BarclaysPeter Lawson	$13	13.8% upside
2024-05-17	BMO CapitalEvan Seigerman	$14	22.6% upside
2022-12-12	BMO Capital	$70	513% upside
2022-12-07	Leerink Partners	$34	197.7% upside
2022-10-03	Leerink Partners	$30	162.7% upside
2022-08-17	Piper Sandler	$43	276.5% upside
2022-08-05	Leerink Partners	$37	224% upside
2022-05-20	Leerink Partners	$48	320.3% upside

Replimune Group (REPL) FAQ

As of the most recent data, REPL shows a target price of $16. Scroll down for historical charts and peer comparison views.

If Replimune Group moved to the average analyst target of $16, shares would be roughly 35.7% higher than $11.42. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Replimune Group's earnings trajectory.

Besides this target price page, Stockcircle has Replimune Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $16) with ownership activity and broader fundamentals.

Replimune Group's target price is $16; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.